Myeloproliferative Disorders Clinical Trials This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

Ultrasound Examination for Spleen Volume Evaluation in Myeloproliferative Neoplasms
Conditions: Myeloproliferative Neoplasm; Polycythemia Vera; Essential Thrombocythemia; Primary Myelofibrosis; Prefibrotic/Early Primary Myelofibrosis Interventions: Diagnostic Test: ULTRASOUND EXAM AND MRI SCAN Sponsors: Federico II University Completed (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 17, 2024 Category: Research Source Type: clinical trials

Functional and Phenotypic Characterization of Monocytes in Myeloproliferative Syndromes
Conditions: Myeloproliferative Neoplasm; Polycythemia Vera; Essential Thrombocythemia; Primary Myelofibrosis Interventions: Diagnostic Test: Monocytes signatures in myeloproliferative neoplasms at diagnosis Sponsors: University Hospital, Angers Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 12, 2024 Category: Research Source Type: clinical trials

A Prospective Patient Reported Outcomes and Wearables Study in Myeloproliferative Neoplasms
Conditions: Myeloproliferative Neoplasm Sponsors: Guy ' s and St Thomas ' NHS Foundation Trust Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - March 28, 2024 Category: Research Source Type: clinical trials

Trial of 2 Step ATG for Acute GVHD Prevention Post Myeloablative Allogeneic Stem Cell Transplant
Conditions: GVHD,Acute; Acute Leukemia; Myelodysplastic Syndromes; Myeloproliferative Disorders Interventions: Drug: ATG Combined with Tacrolimus and Mini Methotrexate Sponsors: University of Alabama at Birmingham Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - March 18, 2024 Category: Research Source Type: clinical trials

A Study to Evaluate the Safety, Tolerability of INCB160058 in Participants With Myeloproliferative Neoplasms
Conditions: Myeloproliferative Neoplasms Interventions: Drug: INCB160058 Sponsors: Incyte Corporation Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - March 15, 2024 Category: Research Source Type: clinical trials

Pacritinib, a Kinase Inhibitor of CSF1R, IRAK1, JAK2, and FLT3, in Adults and Pediatric Participants 12 Years of Age or Older With Myelodysplastic Syndromes or Myelodysplastic/Myeloproliferative Neoplasms
Conditions: Myelodysplastic Syndromes Interventions: Drug: pacritinib Sponsors: National Cancer Institute (NCI) Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - March 11, 2024 Category: Research Source Type: clinical trials

Efficacy and Safety of Ropeginterferon Alfa 2b (P1101) for Patients With Low-Risk Polycythemia Vera
Conditions: Polycythemia Vera; Myeloproliferative Neoplasm Interventions: Drug: Ropeginterferon alfa-2b; Procedure: Phlebotomy Sponsors: PharmaEssentia Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - March 4, 2024 Category: Research Source Type: clinical trials

Ivosidenib and Ruxolitinib in Patients With Advanced Blood Cancers That Have IDH1 Gene MutationPhase MPNs
Conditions: Myeloproliferative Neoplasms Interventions: Drug: Ivosidenib; Drug: Ruxolitinib Sponsors: University of Chicago Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - March 4, 2024 Category: Research Source Type: clinical trials

Phase I/II Study of a Combination of Decitabine and Cedazuridine (ASTX727) and ASTX029, an ERK Inhibitor, for Patients With RAS Pathway Mutant Myelodysplastic Syndromes and Myelodysplastic/Myeloproliferative Neoplasms
Conditions: Pathway Mutant Myelodysplastic Syndromes; Myelodysplastic Neoplasm; Myeloproliferative Neoplasm Interventions: Drug: ASTX029; Drug: ASTX727 Sponsors: M.D. Anderson Cancer Center Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 29, 2024 Category: Research Source Type: clinical trials

Trial of 2 Step ATG for Prevention of Acute GVHD Post Allogeneic Stem Cell Transplant
Conditions: Acute Leukemia; Myelodysplastic Syndrome; Myeloproliferative Disorders Interventions: Drug: ATG dosing platform when combined with standard tacrolimus and mini methotrexate Sponsors: University of Alabama at Birmingham Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 19, 2024 Category: Research Source Type: clinical trials

Functional Characterization of Thrombopoietin/cMPL Receptor Mutations in Myeloproliferative Neoplasia
Conditions: Myeloproliferative Disorder Interventions: Other: Gene sequencing Sponsors: Centre Hospitalier Universitaire de N īmes Active, not recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 7, 2024 Category: Research Source Type: clinical trials

Pacritinib w/ Talazoparib in Pts w/ Myeloproliferative Neoplasms Unresponsive to JAK2 Inhibition
Conditions: Primary Myelofibrosis; Post-polycythemia Vera Myelofibrosis; Post-essential Thrombocythemia Myelofibrosis; Chronic Myelomonocytic Leukemia; Polycythemia Vera; Essential Thrombocytosis Interventions: Drug: Talazoparib; Drug: pacritinib Sponsors: Fox Chase Cancer Center Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - January 23, 2024 Category: Research Source Type: clinical trials

A New Blood Score for Myelofibrosis Staging
Conditions: Myeloproliferative Neoplasm Interventions: Diagnostic Test: Blood sampling Sponsors: Assistance Publique - H ôpitaux de Paris Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - December 20, 2023 Category: Research Source Type: clinical trials

Prevalence study of pnh clones in patients with neoplasies
Conditions: Myeloproliferative Neoplasm Sponsors: AUSL Romagna Rimini Completed (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - December 7, 2023 Category: Research Source Type: clinical trials

A Study of JNJ-88549968 for the Treatment of Calreticulin (CALR)-Mutated Myeloproliferative Neoplasms
Conditions: Myeloproliferative Disorders; Essential Thrombocythemia; Neoplasms; Myelofibrosis Interventions: Drug: JNJ-88549968 Sponsors: Janssen Research& Development, LLC Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - November 29, 2023 Category: Research Source Type: clinical trials